New drug cocktail aims to slow kidney disease

NCT ID NCT06350123

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding balcinrenone to the standard drug dapagliflozin helps people with chronic kidney disease more than dapagliflozin alone. 324 adults with kidney disease and protein in their urine took either a combination pill or dapagliflozin alone for 12 weeks. Researchers measured changes in urine protein levels to see if the combo works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: balcinrenone combined with dapagliflozin
What this could lead to: If successful, this could lead to a more effective treatment option for chronic kidney disease by reducing protein in urine better than current standard therapy.
What could go wrong: This is an early dose-finding study (Phase IIb) with only 324 participants. The combination may not prove significantly better than dapagliflozin alone, and side effects or tolerability issues could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Research Site

Sheffield, Alabama, 35660, United States
Research Site

Glendale, California, 91206, United States
Research Site

Waterbury, Connecticut, 06708, United States
Research Site

Hialeah, Florida, 33012, United States
Research Site

Miami Lakes, Florida, 33014, United States
Research Site

Annapolis, Maryland, 21401, United States
Research Site

New Bern, North Carolina, 28562, United States
Research Site

El Paso, Texas, 79935, United States
Research Site

Houston, Texas, 77079, United States
Research Site

Houston, Texas, 77099, United States
Research Site

San Antonio, Texas, 78212, United States
Research Site

Ogden, Utah, 84405, United States
Research Site

Salt Lake City, Utah, 84115, United States
Research Site

Salt Lake City, Utah, 84124, United States
Research Site

Norfolk, Virginia, 23504, United States
Research Site

Linz, 4021, Austria
Research Site

Sankt Pölten, 3100, Austria
Research Site

Vienna, 1030, Austria
Research Site

Vienna, 1130, Austria
Research Site

Vienna, 1190, Austria
Research Site

Vienna, A-1090, Austria
Research Site

Wels, 4600, Austria
Research Site

Porto Alegre, 90020-090, Brazil
Research Site

São Paulo, 01228-000, Brazil
Research Site

São Paulo, 04012-909, Brazil
Research Site

São Paulo, 04038-031, Brazil
Research Site

São Paulo, 05403-9000, Brazil
Research Site

Burgas, 8018, Bulgaria
Research Site

Dobrich, 9300, Bulgaria
Research Site

Pleven, 5800, Bulgaria
Research Site

Plovdiv, 4000, Bulgaria
Research Site

Sofia, 1680, Bulgaria
Research Site

London, Ontario, N6A 5A5, Canada
Research Site

Waterloo, Ontario, N2T 0C1, Canada
Research Site

Montreal, Quebec, H4J 1C5, Canada
Research Site

Québec, Quebec, G1R 2J6, Canada
Research Site

Changchun, 130021, China
Research Site

Changzhou, 213004, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200050, China
Research Site

Tianjin, 300050, China
Research Site

Bari, 70124, Italy
Research Site

Bologna, 40138, Italy
Research Site

Genoa, 16132, Italy
Research Site

Pavia, 27100, Italy
Research Site

Ageo, 362-8588, Japan
Research Site

Fujisawa-shi, 251-0041, Japan
Research Site

Fukuoka, 810-8563, Japan
Research Site

Koga-shi, 306-0232, Japan
Research Site

Koshigaya-shi, 343-8577, Japan
Research Site

Kumamoto, 860-0008, Japan
Research Site

Nagasaki, 852-8034, Japan
Research Site

Nagoya, 451-8511, Japan
Research Site

Okinawa-shi, 904-2143, Japan
Research Site

Takamatsu, 760-0076, Japan
Research Site

Zentsuji-shi, 765-8507, Japan
Research Site

Ipoh, 30990, Malaysia
Research Site

Johor Bahru, 80100, Malaysia
Research Site

Kajang, 43000, Malaysia
Research Site

Kota Bharu, 15586, Malaysia
Research Site

Kuala Terengganu, 20400, Malaysia
Research Site

Bialystok, 15-481, Poland
Research Site

Grodzisk Mazowiecki, 05-825, Poland
Research Site

Leżajsk, 37-300, Poland
Research Site

Szczecin, 70-111, Poland
Research Site

Warsaw, 02-798, Poland
Research Site

Żywiec, 34-300, Poland
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08036, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Palma de Mallorca, 07010, Spain
Research Site

Valencia, 46026, Spain
Research Site

Kaohsiung City, 80756, Taiwan
Research Site

New Taipei City, 220, Taiwan
Research Site

Taichung, 40201, Taiwan
Research Site

Tainan, 710, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taipei, 11490, Taiwan
Research Site

Ankara, 06340, Turkey (Türkiye)
Research Site

Gaziantep, 27310, Turkey (Türkiye)
Research Site

Kahramanmaraş, 46100, Turkey (Türkiye)
Research Site

Kayseri, 38039, Turkey (Türkiye)
Research Site

Kocaeli, 41380, Turkey (Türkiye)
Research Site

Dundee, DDS 1SY, United Kingdom
Research Site

London, N18 1QX, United Kingdom
Research Site

Newquay, TR7 1RU, United Kingdom
Research Site

Nottingham, NG9 6DX, United Kingdom
Research Site

Haiphong, 180000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Hochiminh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.